Changes in body composition of children with chronic renal failure on growth hormone

Valerie L. Johnson, Jack Wang, Frederick J. Kaskel, Richard N. Pierson

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Body composition is altered in children with chronic renal failure (CRF) and contributes to the significant growth failure seen in these children. Recombinant human growth hormone (rhGH) has been used in the past several years to improve the somatic growth of children with CRF. To determine if the growth achieved in these children occurs concomitantly with body compositional changes, seven prepubertal (n = 6) and pubertal (n = 1) children with chronic renal insufficiency (n = 4) and end-stage renal disease (n = 3) underwent measurements of total body fat (FM), fat free mass (FFM), bone mineral density (BMD), total bone mineral mass (TBBM), total body water (TBW), and total body potassium (TBK) before and 6 months after initiation of subcutaneous recombinant human growth hormone (rhGH) at 0.35 mg/kg per week. The techniques used included dual-energy X-ray absorptiometry (for measurement of FM, BMD, and TBBM), total body potassium counting (for measurement of TBK), and deuterated water for assessment of TBW. Significant increases in both height and weight were seen following 6 months of rhGH therapy. These increases were accompanied by significant reductions in FM (4.4 ± 1.4 kg vs. 3.6 ± 1.2 kg, P = 0.002) and percentage fat (18.6 ± 3.9% vs. 14.5 ± 3.4%, P = 0.04), while FFM (17.9 ± 3.0 kg vs. 20.7 ± 3.6 kg, P = 0.04) increased significantly as did TBBM (776 ± 171 g vs. 844 ± 177 g, P = 0.001). Increases in TBK, a measure of body cell mass, were also seen. No difference in total BMD was observed. Thus, growth in CRF is occurring with repletion of the FFM and TBBM compartments. Despite these improvements, no change was observed in the body mass index (BMI). Measurement of BMI alone does not define the compartmental catabolic losses in FFM.

Original languageEnglish (US)
Pages (from-to)695-700
Number of pages6
JournalPediatric Nephrology
Volume14
Issue number7
StatePublished - Jul 2000

Fingerprint

Body Composition
Growth Hormone
Chronic Kidney Failure
Fats
Human Growth Hormone
Bone Density
Body Water
Growth
Potassium
Body Mass Index
Body Weights and Measures
Photon Absorptiometry
Chronic Renal Insufficiency
Minerals
Adipose Tissue
Weights and Measures
Bone and Bones
Water
Therapeutics

Keywords

  • Body composition
  • Chronic renal failure
  • Dual-energy X-ray absorptiometry
  • Growth
  • Growth hormone

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Changes in body composition of children with chronic renal failure on growth hormone. / Johnson, Valerie L.; Wang, Jack; Kaskel, Frederick J.; Pierson, Richard N.

In: Pediatric Nephrology, Vol. 14, No. 7, 07.2000, p. 695-700.

Research output: Contribution to journalArticle

Johnson, Valerie L. ; Wang, Jack ; Kaskel, Frederick J. ; Pierson, Richard N. / Changes in body composition of children with chronic renal failure on growth hormone. In: Pediatric Nephrology. 2000 ; Vol. 14, No. 7. pp. 695-700.
@article{cf4a15e8dfcc459e9d345d347f9cb30e,
title = "Changes in body composition of children with chronic renal failure on growth hormone",
abstract = "Body composition is altered in children with chronic renal failure (CRF) and contributes to the significant growth failure seen in these children. Recombinant human growth hormone (rhGH) has been used in the past several years to improve the somatic growth of children with CRF. To determine if the growth achieved in these children occurs concomitantly with body compositional changes, seven prepubertal (n = 6) and pubertal (n = 1) children with chronic renal insufficiency (n = 4) and end-stage renal disease (n = 3) underwent measurements of total body fat (FM), fat free mass (FFM), bone mineral density (BMD), total bone mineral mass (TBBM), total body water (TBW), and total body potassium (TBK) before and 6 months after initiation of subcutaneous recombinant human growth hormone (rhGH) at 0.35 mg/kg per week. The techniques used included dual-energy X-ray absorptiometry (for measurement of FM, BMD, and TBBM), total body potassium counting (for measurement of TBK), and deuterated water for assessment of TBW. Significant increases in both height and weight were seen following 6 months of rhGH therapy. These increases were accompanied by significant reductions in FM (4.4 ± 1.4 kg vs. 3.6 ± 1.2 kg, P = 0.002) and percentage fat (18.6 ± 3.9{\%} vs. 14.5 ± 3.4{\%}, P = 0.04), while FFM (17.9 ± 3.0 kg vs. 20.7 ± 3.6 kg, P = 0.04) increased significantly as did TBBM (776 ± 171 g vs. 844 ± 177 g, P = 0.001). Increases in TBK, a measure of body cell mass, were also seen. No difference in total BMD was observed. Thus, growth in CRF is occurring with repletion of the FFM and TBBM compartments. Despite these improvements, no change was observed in the body mass index (BMI). Measurement of BMI alone does not define the compartmental catabolic losses in FFM.",
keywords = "Body composition, Chronic renal failure, Dual-energy X-ray absorptiometry, Growth, Growth hormone",
author = "Johnson, {Valerie L.} and Jack Wang and Kaskel, {Frederick J.} and Pierson, {Richard N.}",
year = "2000",
month = "7",
language = "English (US)",
volume = "14",
pages = "695--700",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Changes in body composition of children with chronic renal failure on growth hormone

AU - Johnson, Valerie L.

AU - Wang, Jack

AU - Kaskel, Frederick J.

AU - Pierson, Richard N.

PY - 2000/7

Y1 - 2000/7

N2 - Body composition is altered in children with chronic renal failure (CRF) and contributes to the significant growth failure seen in these children. Recombinant human growth hormone (rhGH) has been used in the past several years to improve the somatic growth of children with CRF. To determine if the growth achieved in these children occurs concomitantly with body compositional changes, seven prepubertal (n = 6) and pubertal (n = 1) children with chronic renal insufficiency (n = 4) and end-stage renal disease (n = 3) underwent measurements of total body fat (FM), fat free mass (FFM), bone mineral density (BMD), total bone mineral mass (TBBM), total body water (TBW), and total body potassium (TBK) before and 6 months after initiation of subcutaneous recombinant human growth hormone (rhGH) at 0.35 mg/kg per week. The techniques used included dual-energy X-ray absorptiometry (for measurement of FM, BMD, and TBBM), total body potassium counting (for measurement of TBK), and deuterated water for assessment of TBW. Significant increases in both height and weight were seen following 6 months of rhGH therapy. These increases were accompanied by significant reductions in FM (4.4 ± 1.4 kg vs. 3.6 ± 1.2 kg, P = 0.002) and percentage fat (18.6 ± 3.9% vs. 14.5 ± 3.4%, P = 0.04), while FFM (17.9 ± 3.0 kg vs. 20.7 ± 3.6 kg, P = 0.04) increased significantly as did TBBM (776 ± 171 g vs. 844 ± 177 g, P = 0.001). Increases in TBK, a measure of body cell mass, were also seen. No difference in total BMD was observed. Thus, growth in CRF is occurring with repletion of the FFM and TBBM compartments. Despite these improvements, no change was observed in the body mass index (BMI). Measurement of BMI alone does not define the compartmental catabolic losses in FFM.

AB - Body composition is altered in children with chronic renal failure (CRF) and contributes to the significant growth failure seen in these children. Recombinant human growth hormone (rhGH) has been used in the past several years to improve the somatic growth of children with CRF. To determine if the growth achieved in these children occurs concomitantly with body compositional changes, seven prepubertal (n = 6) and pubertal (n = 1) children with chronic renal insufficiency (n = 4) and end-stage renal disease (n = 3) underwent measurements of total body fat (FM), fat free mass (FFM), bone mineral density (BMD), total bone mineral mass (TBBM), total body water (TBW), and total body potassium (TBK) before and 6 months after initiation of subcutaneous recombinant human growth hormone (rhGH) at 0.35 mg/kg per week. The techniques used included dual-energy X-ray absorptiometry (for measurement of FM, BMD, and TBBM), total body potassium counting (for measurement of TBK), and deuterated water for assessment of TBW. Significant increases in both height and weight were seen following 6 months of rhGH therapy. These increases were accompanied by significant reductions in FM (4.4 ± 1.4 kg vs. 3.6 ± 1.2 kg, P = 0.002) and percentage fat (18.6 ± 3.9% vs. 14.5 ± 3.4%, P = 0.04), while FFM (17.9 ± 3.0 kg vs. 20.7 ± 3.6 kg, P = 0.04) increased significantly as did TBBM (776 ± 171 g vs. 844 ± 177 g, P = 0.001). Increases in TBK, a measure of body cell mass, were also seen. No difference in total BMD was observed. Thus, growth in CRF is occurring with repletion of the FFM and TBBM compartments. Despite these improvements, no change was observed in the body mass index (BMI). Measurement of BMI alone does not define the compartmental catabolic losses in FFM.

KW - Body composition

KW - Chronic renal failure

KW - Dual-energy X-ray absorptiometry

KW - Growth

KW - Growth hormone

UR - http://www.scopus.com/inward/record.url?scp=0034130351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034130351&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 695

EP - 700

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 7

ER -